Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma

Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor cells. The phase II HORIZON trial evaluated the efficacy of melflufen plus dexamethasone in relapsed and refractory multiple mye...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Richardson, Paul G., Oriol, Albert, Larocca, Alessandra, Bladé, Joan, Cavo, Michele, Rodriguez-Otero, Paula, Leleu, Xavier, Nadeem, Omar, Hiemenz, John W., Hassoun, Hani, Touzeau, Cyrille, Alegre, Adrián, Paner, Agne, Maisel, Christopher, Mazumder, Amitabha, Raptis, Anastasios, Moreb, Jan S., Anderson, Kenneth C., Laubach, Jacob P., Thuresson, Sara, Thuresson, Marcus, Byrne, Catriona, Harmenberg, Johan, Bakker, Nicolaas A., Mateos, María-Victoria
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2021
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8078327/
https://ncbi.nlm.nih.gov/pubmed/33296242
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.02259
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars